← Leaderboards
Elizabeth Ottinger
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadToxicologyTherapeutics For Rare And Neglected DiseasesGenesPharmaceutical PreparationsClinical TrialsMouse ModelInvestigational New Drug ApplicationResearch PersonnelAnimal ModelUnited States National Institutes Of HealthPreventFormulationRare DiseasesScientistAffectMutationManufactureCollaborationsCessation Of LifePreclinical DevelopmentDrug KineticsPeptidesPhenotype
Grant awards (41)
Gene Therapy Platform for Rare Diseases$2,824,145
ZIA · FY2025 · TR · contact PI
Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations$931,631
ZIA · FY2025 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$533,452
ZIA · FY2025 · TR · contact PI
Gene Therapy Platform for Rare Diseases$2,652,815
ZIA · FY2024 · TR · contact PI
A Treatment for Patients with Jansens Metaphyseal Chondrodysplasia (JMC)$1,800,000
ZIA · FY2024 · TR · contact PI
Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations$1,100,000
ZIA · FY2024 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$1,066,907
ZIA · FY2024 · TR · contact PI
Antisense Oligonucleotide (ASO) Development for Rare and Neglected Diseases$1,066,904
ZIA · FY2024 · TR · contact PI
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2$125,000
ZIA · FY2024 · TR · contact PI
Helping to End Addiction Long-term (HEAL): Development of Clinical Candidate Drugs for Pain, Addiction and Overdose$8,627,631
ZIA · FY2023 · TR · contact PI
Gene Therapy Platform for Rare Diseases$6,029,283
ZIA · FY2023 · TR · contact PI
A Treatment for Patients with Jansens Metaphyseal Chondrodysplasia (JMC)$2,266,482
ZIA · FY2023 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$1,599,529
ZIA · FY2023 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$1,446,525
ZIA · FY2023 · TR · contact PI
Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations$1,408,504
ZIA · FY2023 · TR · contact PI
Antisense Oligonucleotide (ASO) Development for Rare and Neglected Diseases$1,088,000
ZIA · FY2023 · TR · contact PI
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2$161,896
ZIA · FY2023 · TR · contact PI
A Treatment for Patients with Jansens Metaphyseal Chondrodysplasia (JMC)$3,966,484
ZIA · FY2022 · TR · contact PI
Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations$1,706,465
ZIA · FY2022 · TR · contact PI
A Treatment for Patients with Jansens Metaphyseal Chondrodysplasia (JMC)$3,162,551
ZIA · FY2021 · TR · contact PI
Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations$1,311,385
ZIA · FY2021 · TR · contact PI
A Treatment for Patients with Jansens Metaphyseal Chondrodysplasia$1,866,230
ZIA · FY2020 · TR · contact PI
Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations$1,764,300
ZIA · FY2020 · TR · contact PI
A Protein Replacement Drug for Friedreich's Ataxia$1,463,021
ZIA · FY2020 · TR · contact PI
LUM-001 as a Treatment for Creatine Transporter Deficiency$2,756,223
ZIA · FY2019 · TR · contact PI
A Protein Replacement Drug for Friedreichs Ataxia$1,008,626
ZIA · FY2019 · TR · contact PI
Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with Noonan Syndrome with Multiple Lentigines (NSML)$995,100
ZIA · FY2019 · TR · contact PI
LUM-001 as a Treatment for Creatine Transporter Deficiency$2,986,326
ZIA · FY2018 · TR · contact PI
A Protein Replacement Drug for Friedreichs Ataxia$1,008,626
ZIA · FY2018 · TR · contact PI
Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with Noonan Syndrome with Multiple Lentigines (NSML)$995,100
ZIA · FY2018 · TR · contact PI
LUM-001 as a Treatment for Creatine Transporter Deficiency$2,853,144
ZIA · FY2017 · TR · contact PI
A Protein Replacement Drug for Friedreichs Ataxia$2,453,144
ZIA · FY2017 · TR · contact PI
Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with LEOPARD Syndrome$2,453,144
ZIA · FY2017 · TR · contact PI
Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with LEOPARD Syndrome$1,765,116
ZIA · FY2016 · TR · contact PI
LUM-001 as a Treatment for Creatine Transporter Deficiency$1,765,116
ZIA · FY2016 · TR · contact PI
Cyclodextrin for Niemann-Pick Type C1 Disease$1,765,116
ZIA · FY2016 · TR · contact PI
A Protein Replacement Drug for Friedreichs Ataxia$1,417,065
ZIA · FY2016 · TR · contact PI
CincY as a Treatment for Creatine Transporter Defect$2,003,778
ZIA · FY2015 · TR · contact PI
Cyclodextrin for Niemann-Pick Type C1 Disease$2,003,778
ZIA · FY2015 · TR · contact PI
Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with LEOPARD Syndrome$2,003,778
ZIA · FY2015 · TR · contact PI
Development of the Novel Antifungal VT-1129 for Cryptococcal Meningitis$417,192
ZIA · FY2015 · TR · contact PI